TRINITY BIOTECH PLC

Trinity Biotech plc announced a strategic collaboration with Latch Medical Limited to develop biosensor-guided precision drug delivery solutions. This partnership will integrate Trinity Biotech's AI-native CGM+ wearable biosensor platform with Latch Medical's Pharma Latch™ intradermal drug delivery technology to create next-generation metabolic health solutions for conditions like diabetes and obesity. As part of the collaboration, Trinity Biotech will also make a strategic equity investment in Latch Medical, supported by its largest financial investor, Perceptive Advisors.

Trinity Biotech plc announced a strategic collaboration agreement with Latch Medical Limited to develop next-generation metabolic health solutions. The partnership will combine Trinity Biotech's AI-native CGM+ wearable biosensor platform with Latch Medical's innovative Pharma Latch™ intradermal drug delivery technology. This aims to create personalized and responsive treatment approaches for conditions like diabetes and obesity. As part of the collaboration, Trinity Biotech will also make a strategic equity investment in Latch Medical, supported by its largest financial investor, Perceptive Advisors.

Trinity Biotech plc announced a change in the ratio of its American depositary shares (ADSs) from 1 ADS representing 20 Class A ordinary shares to 1 ADS representing 600 Class A ordinary shares. This change will have the effect of a 1-for-30 reverse ADS split for current holders. The company aims to regain compliance with Nasdaq's $1.00 minimum bid price requirement and attract a broader investor base. The change is expected to take effect on July 24, 2026, with fractional entitlements to new ADSs being sold and proceeds distributed.

Trinity Biotech announced positive clinical study results for its next-generation CGM+ wearable biosensor platform. The analysis of over 5,000 hours of clinical wear data validated the device's ability to distinguish nocturnal compression-related false low glucose events from true blood glucose lows. This capability addresses a common limitation of conventional CGM systems, improving user experience by reducing false alarms and providing richer data for automated insulin delivery systems. The company believes this strengthens the differentiation and commercial opportunity for its CGM+ solution, which is in the latter stages of development.

Trinity Biotech plc announced positive clinical trial data for its CGM+ solution. The analysis of over 5,000 hours of wear data validated CGM+'s ability to distinguish nocturnal compression-related false low glucose events from true blood glucose lows. This capability addresses a common limitation of conventional continuous glucose monitoring systems, improving user experience and strengthening the commercial opportunity for CGM+ within the global CGM market. The company plans to incorporate this function into CGM+ as it moves towards pivotal trials and regulatory submission.

Trinity Biotech announced that its subsidiary, Trinovium, has secured Silver Membership in the Open Compute Project (OCP). This membership provides Trinovium with a crucial platform to engage directly with the global AI data center ecosystem, aiming to accelerate product development and enhance market access for its liquid cooling solutions. The data center liquid cooling market is projected to grow significantly from $4 billion in 2026 to $27 billion by 2033, representing a 31.5% CAGR. Trinovium plans to leverage Trinity Biotech's existing expertise and manufacturing capacity to capitalize on this growth.

Trinity Biotech PLC announced the termination of its Standby Equity Purchase Agreement with YA II PN, LTD., an affiliate of Yorkville Advisors Global. The company delivered notice of this termination on June 29, 2026. This action impacts the company's equity financing arrangements.

Trinity Biotech plc announced the formal termination of its Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD., an affiliate of Yorkville Advisors Global. This agreement was an equity line of credit facility. The company stated it does not intend to utilize the SEPA further, indicating the termination aligns with its current financing strategy.

Trinity Biotech plc announced the launch of Trinovium, a new subsidiary dedicated to advanced liquid cooling solutions and fluid intelligence systems for AI data centers. Trinovium will leverage Trinity's existing expertise in ultra-high-purity fluid manufacturing, analytical technologies, and large-scale production capabilities. This move targets the rapidly growing data center liquid cooling market, projected to expand from $4 billion in 2026 to $27 billion by 2033, driven by increasing AI compute density. The initiative aims to provide a capital-efficient path into this market and create potential for additional operating leverage from existing assets.

Trinity Biotech announced it has been awarded significant orders for over 2 million TrinScreen HIV tests, reinforcing strong demand and supporting 2026 revenue and profitability targets. Concurrently, the company reported its Q1 2026 financial results, with revenues increasing 43% to $10.8 million, driven by strong rapid HIV and haemoglobin product sales. The company also achieved substantial year-on-year gross margin percentage improvements and significantly reduced its net loss and negative Adjusted EBITDA, reflecting progress in its Comprehensive Transformation Plan.